Is there any information on clearance from the body? Are there any problems with renal or liver dysfunction?

The PreCardix® clinical trial participants were a healthy baseline population with no co-morbidities. Patients with pre-existing medical conditions, including renal or liver dysfunction, were not studied. Patients with pre-existing co-morbidities should consult with their health care provider before starting PreCardix® and be closely monitored if they do begin taking it. A 24-hour collection of urine sodium, urine creatinine, and urine volume happened at baseline and week 8 of the clinical trial study. Serum testing including CBC, glucose, creatinine, an estimate of glomerular filtration rate, sodium, potassium, chloride, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, and bilirubin happened at screening and eight weeks. There were no clinically significant differences in the placebo and treatment groups. Pre-clinical toxicity trials on animal models (rats) found no resulting safety issues or hypotension when subjects received a daily dosage 100 times higher than that recommended.